Surgery: Current Research

ISSN - 2161-1076


Old Immunosuppressive Agents: Newer Approach in liver Transplant Recipients to Achieve Rejection Free and Nephron Preserving Protocol

Ashok Kumar Jain and Amar Nath Mukerji

In liver transplant (LTx) recipient bioavailability of oral Mycophenolate Mofetil (MMF) is less than 48% in first weeks post LTx week. Intravenous (IV) MMF allows 100% bioavailability with higher peak values. Use of MMF in immediate post LTX period allows delayed introduction of tacrolimus which allows preserving the renal function and reversing the pre-existing renal dysfunction promptly after successful LTx without use of antibody preparation and at no risk of precipitating acute cellular rejection.